• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Black Diamond Therapeutics Inc. (Amendment)

    5/13/24 7:09:49 PM ET
    $BDTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BDTX alert in real time by email
    SC 13D/A 1 nea16-bldiamond_18839.htm NEW ENTERPRISE ASSOCIATES 16, L.P. / BLACK DIAMOND THERAPEUTICS, INC. -- SCHEDULE 13D/A(#1) Schedule 13D

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Black Diamond Therapeutics, Inc.

    (Name of Issuer)

    Common Stock, $0.0001 par value

    (Title of Class of Securities)

    09203E105

    (CUSIP Number)

    Stephanie Brecher

    New Enterprise Associates

    1954 Greenspring Drive, Suite 600

    Timonium, MD 21093

    (410) 842-4000

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

    May 9, 2024

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No. 09203E105

    13D Page 2 of 21 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    New Enterprise Associates 16, L.P.

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    WC

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware Limited Partnership

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    4,448,757 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    4,448,757 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,448,757 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    7.9%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    PN

     

       

     

     

     

    CUSIP No. 09203E105

    13D Page 3 of 21 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    NEA Partners 16, L.P.

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware Limited Partnership

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    4,448,757 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    4,448,757 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,448,757 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    7.9%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    PN

     

       

     

     

     

     

     CUSIP No. 09203E105

    13D Page 4 of 21 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    NEA 16 GP, LLC

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware Limited Liability Company

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    4,448,757 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    4,448,757 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,448,757 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    7.9%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    OO

     

       

     

     

     

      

      CUSIP No. 09203E105

    13D Page 5 of 21 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Forest Baskett

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    4,448,757 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    4,448,757 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,448,757 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    7.9%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

     

    CUSIP No. 09203E105

    13D Page 6 of 21 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Ali Behbahani

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    98,190 Shares

     

      8.  

    SHARED VOTING POWER

     

    4,448,757 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    98,190 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    4,448,757 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,546,947 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    8.1%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

     

    CUSIP No. 09203E105

    13D Page 7 of 21 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Carmen Chang

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    4,448,757 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    4,448,757 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,448,757 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    7.9%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

     

     

    CUSIP No. 09203E105

    13D Page 8 of 21 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Anthony A. Florence, Jr.

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    4,448,757 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    4,448,757 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,448,757 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    7.9%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

     

    CUSIP No. 09203E105

    13D Page 9 of 21 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Mohamad H. Makhzoumi

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    4,448,757 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

        4,448,757 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

         4,448,757 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    7.9%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

    CUSIP No. 09203E105

    13D Page 10 of 21 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Scott D. Sandell

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    4,448,757 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    4,448,757 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,448,757 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    7.9%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

     

    CUSIP No. 09203E105

    13D Page 11 of 21 Pages    

     

    1.  

    NAMES OF REPORTING PERSONS.

     

    Paul Walker

     

       
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions)

     

     

     

     

    (a) ☐

    (b) ☐

    3.  

    SEC USE ONLY

     

     

     

       
    4.  

    SOURCE OF FUNDS (see instructions)

      

    AF

     

       
    5.  

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e)     

     

     

     

       ☐
    6.  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

      

       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH  

     7.

     

    SOLE VOTING POWER

     

    0 Shares

     

      8.  

    SHARED VOTING POWER

     

    4,448,757 Shares

     

      9.  

    SOLE DISPOSITIVE POWER

     

    0 Shares

     

      10.  

    SHARED DISPOSITIVE POWER

     

    4,448,757 Shares

     

    11.  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    4,448,757 Shares

     

       
    12.  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (see instructions)    

     

     

     

       ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

      

    7.9%

     

       

     14.

     

    TYPE OF REPORTING PERSON (see instructions)

       

    IN

     

       

     

     

     

     

    CUSIP No. 09203E105

    13D Page 12 of 21 Pages    

     

    Item 1.  Security and Issuer.

    This Amendment No. 1 to Schedule 13D amends and supplements the Schedule 13D originally filed on February 13, 2020 and relates to the common shares, $0.0001 par value (“Common Stock”), of Black Diamond Therapeutics, Inc. (the “Issuer”), having its principal executive office at One Main Street, 14th Floor, Cambridge, MA 02142.

     

    Certain terms used but not defined in this Amendment No. 1 have the meanings assigned thereto in the Schedule 13D. Except as specifically provided herein, this Amendment No. 1 does not modify any of the information previously reported on the Schedule 13D.

     

    This Amendment No. 1 is being filed to report that the beneficial ownership of Common Stock by the Reporting Persons (as defined below) has decreased by more than 1% as a result of an increase in the number of Common Stock outstanding. 

     

     

    Item 2.  Identity and Background.

    This statement is being filed by:

     

    (a) New Enterprise Associates 16, L.P. (“NEA 16”), NEA Partners 16, L.P. (“NEA Partners 16”), which is the sole general partner of NEA 16; and NEA 16 GP, LLC (“NEA 16 LLC” and together with NEA Partners 16, the “Control Entities”), which is the sole general partner of NEA Partners 16; and

     

    (b) Forest Baskett (“Baskett”), Ali Behbahani (“Behbahani”), Carmen Chang (“Chang”), Anthony A. Florence, Jr. (“Florence”), Mohamad H. Makhzoumi (“Makhzoumi”), Scott D. Sandell (“Sandell”), and Paul Walker (“Walker”) (together, the “Managers”), Joshua Makower (“Makower”) and Peter W. Sonsini (“Sonsini”). The Managers are the managers of NEA 16 LLC.

     

    The persons named in this Item 2 are referred to individually herein as a “Reporting Person” and collectively as the “Reporting Persons.”

     

    The address of the principal business office of NEA 16, each Control Entity and Sandell is New Enterprise Associates, 1954 Greenspring Drive, Suite 600, Timonium, MD 21093. The address of the principal business office of Baskett, Behbahani, Chang, Makhzoumi, and Walker is New Enterprise Associates, 2855 Sand Hill Road, Menlo Park, CA 94025. The address of the principal business office of Florence is New Enterprise Associates, 104 5th Avenue, 19th Floor, New York, NY 10011.

     

    The principal business of NEA 16 is to invest in and assist growth-oriented businesses located principally in the United States. The principal business of NEA Partners 16 is to act as the sole general partner of NEA 16. The principal business of NEA 16 LLC is to act as the sole general partner of NEA Partners 16. The principal business of each of the Managers is to manage the Control Entities, NEA 16 and a number of affiliated partnerships with similar businesses.

     

    During the five years prior to the date hereof, none of the Reporting Persons has been convicted in a criminal proceeding or has been a party to a civil proceeding ending in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    NEA 16 LLC is a limited liability company organized under the laws of the State of Delaware. NEA 16 and NEA Partners 16 are limited partnerships organized under the laws of the State of Delaware. Each of the Managers is a United States citizen. 

     

     

     

     

     

     

    CUSIP No. 09203E105

    13D Page 13 of 21 Pages    

     

     

     

     

    Item 3.  Source and Amount of Funds or Other Consideration

    Not applicable.

     

     

    Item 4.  Purpose of Transaction.

    Not applicable.

     

      

    Item 5.  Interest in Securities of the Issuer.

    (a)NEA 16 is the record owner of the NEA 16 Shares. As the general partner of NEA 16, NEA Partners 16 may be deemed to own beneficially the NEA 16 Shares. As the sole general partner of NEA Partners 16, NEA 16 LLC may be deemed to own beneficially the NEA 16 Shares. As members of NEA 16 LLC, each of the Managers may be deemed to own beneficially the NEA 16 Shares.

    Each Reporting Person disclaims beneficial ownership of the NEA 16 Shares other than those shares which such person owns of record.

    As of May 13, 2024, Behbahani is the record owner of 51,690 shares of Common Stock and is the record owner of options to purchase 46,500 shares of Common Stock exercisable within 60 days (the “Behbahani Option Shares”).

    The percentage of outstanding Common Stock of the Issuer which may be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Person’s cover sheet. Such percentage was calculated based on 56,252,794 shares of Common Stock reported by the Issuer to be outstanding as of May 6, 2024, on the Issuer’s Form 10-Q filed with the SEC on May 9, 2024. The percentage set forth on the cover sheet for Behbahani is calculated based on the shares described in the preceding sentence plus the Behbahani Option Shares.

    (b)Regarding the number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote: See line 7 of cover sheets

     

    (ii)shared power to vote or to direct the vote: See line 8 of cover sheets

     

    (iii)sole power to dispose or to direct the disposition: See line 9 of cover sheets

     

    (iv)shared power to dispose or to direct the disposition: See line 10 of cover sheets

     

    (c)

    On March 15, 2024, Behbahani received 3,166 shares of Common Stock for his service as a member of the Board of Directors of the Issuer. These shares were issued in accordance with the Issuer’s Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which Behbahani elected to receive shares of Common Stock in lieu of cash compensation for annual services as a non-employee director of the Issuer.

     

    On May 16, 2023, Behbahani was granted a stock option to purchase 16,500 shares of Common Stock at $1.82 per share for his service as a member of the Board of Directors of the Issuer. The shares subject to this option are expected to vest and become exercisable in full on May 16, 2024, subject to Bebahani’s continued service on such vesting date.

     

    (d)

    No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, Common Stock beneficially owned by any of the Reporting Persons.

     

    (e)

    Each of Makower and Sonsini has ceased to beneficially own five percent (5%) or more of the Issuer’s Common Stock as a result of ceasing to be a manager of NEA 16 LLC.

     

     

     

     

     

    CUSIP No. 09203E105

    13D Page 14 of 21 Pages    

     

     

     

     

    Item 6.  Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

    Not applicable.

     

     

    Item 7.  Material to be Filed as Exhibits.

    Exhibit 1 – Agreement regarding filing of joint Schedule 13D.

    Exhibit 2 – Power of Attorney regarding filings under the Securities Exchange Act of 1934, as amended.

    Exhibit 3 – Power of Attorney on behalf of Joshua Makower regarding filings under the Securities Exchange Act of 1934, as amended. 

     

     

     

     

     

     

     

     

     

     

     

    CUSIP No. 09203E105

    13D Page 15 of 21 Pages    

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    EXECUTED this 13th day of May, 2024.

     

     

    NEW ENTERPRISE ASSOCIATES 16, L.P.

     

    By:

    NEA PARTNERS 16, L.P.

    General Partner

     

    By:

    NEA 16 GP, LLC

    General Partner

      

      By:                             *                                

     Anthony A. Florence, Jr.

     Managing Partner and Co-Chief Executive Officer 

       

      By:                             *                                

     Mohamad Makhzoumi

     Managing Partner and Co-Chief Executive Officer  

     

     

    NEA PARTNERS 16, L.P.

     

    By:NEA 16 GP, LLC
    General Partner

     

      By:                             *                                

     Anthony A. Florence, Jr.

     Managing Partner and Co-Chief Executive Officer 

       

      By:                             *                                

     Mohamad Makhzoumi

     Managing Partner and Co-Chief Executive Officer 

      

     

      

    NEA 16 GP, LLC

     

    By:                             *                                

    Anthony A. Florence, Jr.

    Managing Partner and Co-Chief Executive Officer 

       

    By:                             *                                

    Mohamad Makhzoumi

    Managing Partner and Co-Chief Executive Officer 

     

     

     

     

     

     

    CUSIP No. 09203E105

    13D Page 16 of 21 Pages    

     

     

     

     

     

                     *                        

    Forest Baskett

     

     

                     *                        

    Ali Behbahani

     

     

                     *                        

    Carmen Chang

     

     

                     *                        

    Anthony A. Florence, Jr.

     

     

                     *                        

    Mohamad H. Makhzoumi

     

     

                     *                        

    Joshua Makower

     

     

                     *                        

    Scott D. Sandell

     

     

                     *                        

    Peter W. Sonsini

     

     

                     *                        

    Paul Walker 

     

     

     

     

    */s/ Zachary Bambach           

    Zachary Bambach

    As attorney-in-fact

     

     

    This Amendment No. 1 to Schedule 13D was executed by Zachary Bambach on behalf of the individuals listed above pursuant to Powers of Attorney, copies of which are attached as Exhibit 2 and Exhibit 3.

     

     

     

     
     

     

    CUSIP No. 09203E105

    13D Page 17 of 21 Pages    

     

    EXHIBIT 1

     

    AGREEMENT

     

    Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of shares of stock of Black Diamond Therapeutics, Inc.

     

    EXECUTED this 13th day of May, 2024.

     

     

    NEW ENTERPRISE ASSOCIATES 16, L.P.

     

    By:

    NEA PARTNERS 16, L.P.

    General Partner

     

    By:

    NEA 16 GP, LLC

    General Partner

      

      By:                             *                                

     Anthony A. Florence, Jr.

     Managing Partner and Co-Chief Executive Officer 

       

      By:                             *                                

     Mohamad Makhzoumi

     Managing Partner and Co-Chief Executive Officer  

     

     

    NEA PARTNERS 16, L.P.

     

    By:NEA 16 GP, LLC
    General Partner

     

      By:                             *                                

     Anthony A. Florence, Jr.

     Managing Partner and Co-Chief Executive Officer 

       

      By:                             *                                

     Mohamad Makhzoumi

      

     

      

    NEA 16 GP, LLC

     

    By:                             *                                

    Anthony A. Florence, Jr.

    Managing Partner and Co-Chief Executive Officer 

       

    By:                             *                                

    Mohamad Makhzoumi

     

     

     

     

     

     

     

    CUSIP No. 09203E105

    13D Page 18 of 21 Pages    

     

     

     

     

     

     

                     *                        

    Forest Baskett

     

     

                     *                        

    Ali Behbahani

     

     

                     *                        

    Carmen Chang

     

     

                     *                        

    Anthony A. Florence, Jr.

     

     

                     *                        

    Mohamad H. Makhzoumi

     

     

                     *                        

    Joshua Makower

     

     

                     *                        

    Scott D. Sandell

     

     

                     *                        

    Peter W. Sonsini

     

     

                     *                        

    Paul Walker 

     

     

     

     

    */s/ Zachary Bambach           

    Zachary Bambach

    As attorney-in-fact

     

     

     

    This Agreement relating to Schedule 13D was executed by Zachary Bambach on behalf of the individuals listed above pursuant to a Powers of Attorney copies of which are attached hereto as Exhibit 2 and Exhibit 3.

     

     

     

    CUSIP No. 09203E105

    13D Page 19 of 21 Pages    

    EXHIBIT 2

     

    POWER OF ATTORNEY

     

    KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Zachary Bambach, Nicole Hatcher and Stephanie Brecher, and each of them, with full power to act without the others, his or her true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his or her capacity as a direct or indirect general partner, director, officer or manager of any partnership, corporation or limited liability company, pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any and all regulations promulgated thereunder, including, without limitation, Forms 3, 4 and 5 and Schedules 13D and 13G (and any amendments thereto), and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission (the “SEC”), including, but not limited to, signing a Form ID for and on behalf of the undersigned and filing such Form ID with the SEC, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he or she might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his or her substitutes, may lawfully do or cause to be done by virtue hereof. This power of attorney is perpetual, unless revoked by the undersigned in a signed writing delivered to each of the foregoing attorneys-in-fact. 

     

    IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 29th day of February, 2024.

     

     

    /s/ Peter J. Barris  
    Peter J. Barris  
       
    /s/ Forest Baskett  
    Forest Baskett  
       
    /s/ Ali Behbahani  
    Ali Behbahani  
       
    /s/ Ronald D. Bernal  
    Ronald D. Bernal  
       
    /s/ Ann Bordetsky  
    Ann Bordetsky  
       
    /s/ Carmen Chang  
    Carmen Chang  
       
    /s/ Philip Chopin  
    Philip Chopin  
       
    /s/ Anthony A. Florence, Jr.  
    Anthony A. Florence, Jr.  
       
    /s/ Jonathan Golden  
    Jonathan Golden  
       
    /s/ Scott Gottlieb  
    Scott Gottlieb  

     

     

     

     

     

    CUSIP No. 09203E105

    13D Page 20 of 21 Pages    

     

     

     

    /s/ Mark Hawkins  
    Mark Hawkins  
       
    /s/ Jeffrey R. Immelt  
    Jeffrey R. Immelt  
       
    /s/ Aaron Jacobson  
    Aaron Jacobson  
       
    /s/ Patrick J. Kerins  
    Patrick J. Kerins  
       
    /s/ Hilarie Koplow-McAdams  
    Hilarie Koplow-McAdams  
       
    /s/ Vanessa Larco  
    Vanessa Larco  
       
    /s/ Julio C. Lopez  
    Julio C. Lopez  
       
    /s/ Tiffany Le  
    Tiffany Le  
       
    /s/ Mohamad H. Makhzoumi  
    Mohamad H. Makhzoumi  
       
    /s/ Edward T. Mathers  
    Edward T. Mathers  
       
    /s/ Gregory Papadopoulos  
    Gregory Papadopoulos  
       
    /s/ Kavita Patel  
    Kavita Patel  
       
    /s/ Scott D. Sandell  
    Scott D. Sandell  
       
    /s/ A. Brooke Seawell  
    A. Brooke Seawell  
     
    /s/ Peter Sonsini  

    Peter Sonsini

     
       
    /s/ Melissa Taunton  
    Melissa Taunton  
       
    /s/ Paul E. Walker  
    Paul E. Walker  
       
    /s/ Rick Yang  
    Rick Yang  

     

     

     

    CUSIP No. 09203E105

    13D Page 21 of 21 Pages    

     

    EXHIBIT 3

     

    POWER OF ATTORNEY

     

    KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Zachary Bambach, Nicole Hatcher and Stephanie Brecher, and each of them, with full power to act without the others, his or her true and lawful attorney-in-fact, with full power of substitution, to sign any and all instruments, certificates and documents that may be necessary, desirable or appropriate to be executed on behalf of himself as an individual or in his or her capacity as a direct or indirect general partner, director, officer or manager or former general partner, director, officer or manager of any New Enterprise Associates partnership, corporation or limited liability company, solely with respect to the following entities: Black Diamond Therapeutics, Inc., Inventiva S.A., Marker Therapeutics, Monte Rosa Therapeutics, Inc., and Reneo Pharmaceuticals, Inc. (the “Covered Entities”), pursuant to section 13 or 16 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and any and all regulations promulgated thereunder, including, without limitation, Forms 3, 4 and 5 and Schedules 13D and 13G (and any amendments thereto), and to file the same, with all exhibits thereto, and any other documents in connection therewith, with the Securities and Exchange Commission, and with any other entity when and if such is mandated by the Exchange Act or by the Financial Industry Regulatory Authority, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing necessary, desirable or appropriate, fully to all intents and purposes as he or she might or could do in person, thereby ratifying and confirming all that said attorney-in-fact, or his or her substitutes, may lawfully do or cause to be done by virtue hereof. This power of attorney will last for the duration of the outstanding filing obligations related to the undersigned and NEA Management Company, LLC, and its affiliates. Upon the removal of the undersigned from all outstanding Form 3, 4, and 5, Schedule 13D and 13G or any other similarly related obligatory filings related to the Covered Entities, the power provided herein shall be revoked. 

     

    IN WITNESS WHEREOF, this Power of Attorney has been signed as of the 2nd day of May, 2024.

     

     

    /s/ Joshua Makower  
    Joshua Makower  
       

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Get the next $BDTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BDTX

    DatePrice TargetRatingAnalyst
    7/31/2024$20.00Outperform
    Raymond James
    7/14/2023Overweight
    Piper Sandler
    6/30/2023$2.00 → $10.00Hold → Buy
    Stifel
    6/28/2023$11.00Neutral → Buy
    H.C. Wainwright
    6/27/2023$10.00Neutral → Outperform
    Wedbush
    3/29/2022Outperform → Neutral
    Wedbush
    3/22/2022Buy → Neutral
    H.C. Wainwright
    9/30/2021$10.00Hold
    Stifel
    More analyst ratings

    $BDTX
    Financials

    Live finance-specific insights

    See more
    • Black Diamond Therapeutics Announces Initial Dose Escalation Data Demonstrating Anti-Tumor Activity of BDTX-1535 in Non-Small Cell Lung Cancer Patients Across Multiple EGFR Mutation Families

      BDTX-1535, an epidermal growth factor receptor (EGFR) MasterKey inhibitor, demonstrates clinical proof of activity for MasterKey mutation-targeting approach based on radiographic tumor responses and circulating tumor DNA changes in NSCLC patients with acquired resistance and intrinsic driver EGFR mutations Confirmed radiographic partial response by RECIST 1.1 achieved across predicted therapeutic doses in 5 of 12 NSCLC patients in subgroup with measurable disease, who underwent post baseline tumor assessment by RECIST1.1; one additional patient demonstrated unconfirmed PR awaiting confirmation, while the remaining six patients had stable diseaseExpansion cohorts expected to commence i

      6/27/23 7:00:00 AM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BDTX
    Leadership Updates

    Live Leadership Updates

    See more

    $BDTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors

      SAN DIEGO, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), a self-sustainable, commercial-stage biotechnology company with clinical development programs focusing on a variety of chronic organ diseases, today announced the appointment of David M. Epstein, Ph.D., to Gyre's Board of Directors (the "Board"), effective August 6, 2024. Dr. Epstein will serve as a member of the Audit Committee of the Board and as member of the Compensation Committee of the Board. "We are thrilled to welcome David to the Gyre Board," said Han Ying, Ph.D., Chief Executive Officer of Gyre Therapeutics. "His extensive global experience in biotech companies across the U.S. and Asia will be

      8/8/24 4:05:00 PM ET
      $BDTX
      $GYRE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Black Diamond Therapeutics Announces Changes to Board of Directors

      CAMBRIDGE, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancers, today announced that industry veterans Shannon Campbell and Prakash Raman, Ph.D., have been appointed to the Company's Board of Directors. The Company also announced that Wendy Dixon, Ph.D., and Alex Mayweg, Ph.D., have stepped down as members of its Board of Directors. These changes became effective as of April 10, 2024. "On behalf of the board, I am excited to welcome Shannon and Prakash, both seasoned executives who bring deep and highly relevant oncolog

      4/11/24 8:00:00 AM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

      Presented BDTX-1535 Phase 1 dose escalation data showing durable anti-tumor activity and favorable safety profile in NSCLC patients across heterogeneous EGFR mutations at the October 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsBDTX-1535 NSCLC expansion cohorts enrolling, initial data expected in 2024BDTX-1535 Phase 1 dose escalation data in GBM expected later this yearDosed first patient in a Phase 1 trial of BDTX-4933, a brain-penetrant RAF inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors Cash, cash equivalents, and investments of $144.3 million as of September 30, 2023, expected to be sufficient to fund operations into the fir

      11/6/23 7:45:00 AM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Black Diamond Therapeutics Inc.

      SC 13G/A - Black Diamond Therapeutics, Inc. (0001701541) (Subject)

      11/14/24 1:28:32 PM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Black Diamond Therapeutics Inc.

      SC 13G - Black Diamond Therapeutics, Inc. (0001701541) (Subject)

      11/14/24 12:02:05 PM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Black Diamond Therapeutics Inc.

      SC 13D/A - Black Diamond Therapeutics, Inc. (0001701541) (Subject)

      8/8/24 4:48:56 PM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BDTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Behbahani Ali was granted 7,646 shares, increasing direct ownership by 12% to 70,980 units (SEC Form 4)

      4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)

      3/21/25 4:19:30 PM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Raman Prakash was granted 6,848 shares, increasing direct ownership by 68% to 16,993 units (SEC Form 4)

      4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)

      3/21/25 4:04:02 PM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Biotech Growth N V sold $11,997,749 worth of shares (5,784,292 units at $2.07), decreasing direct ownership by 68% to 2,733,547 units (SEC Form 4)

      4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)

      3/20/25 9:01:40 PM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BDTX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Black Diamond Therapeutics Inc.

      10-Q - Black Diamond Therapeutics, Inc. (0001701541) (Filer)

      5/12/25 4:08:45 PM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Black Diamond Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Black Diamond Therapeutics, Inc. (0001701541) (Filer)

      5/12/25 4:06:33 PM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Black Diamond Therapeutics Inc.

      DEFA14A - Black Diamond Therapeutics, Inc. (0001701541) (Filer)

      4/18/25 4:05:01 PM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BDTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Raymond James initiated coverage on Black Diamond Therapeutics with a new price target

      Raymond James initiated coverage of Black Diamond Therapeutics with a rating of Outperform and set a new price target of $20.00

      7/31/24 6:19:23 AM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Piper Sandler initiated coverage on Black Diamond Therapeutics

      Piper Sandler initiated coverage of Black Diamond Therapeutics with a rating of Overweight

      7/14/23 7:42:17 AM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Black Diamond Therapeutics upgraded by Stifel with a new price target

      Stifel upgraded Black Diamond Therapeutics from Hold to Buy and set a new price target of $10.00 from $2.00 previously

      6/30/23 7:17:14 AM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BDTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Biotech Growth N V bought $934,080 worth of shares (400,000 units at $2.34), increasing direct ownership by 5% to 8,517,839 units (SEC Form 4)

      4 - Black Diamond Therapeutics, Inc. (0001701541) (Issuer)

      10/19/23 3:08:35 PM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BDTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference

      CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced that its Chief Executive Officer, Mark Velleca, M.D., Ph.D., will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2025 in New York, NY. In addition, the company will host one-on-one meetings with investors on the same day. Presentation details are as follows: 4:20-4:50pm ET on Wednesday, June 4 The Webcast will be available at the start of the presentation on the investor relations section of the Compan

      5/29/25 8:00:00 AM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Clinical data on track for Q4 2025 from Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCExpansion of investigator sponsored Phase 0/1 trial into newly diagnosed glioblastoma patients with EGFR alterations initiated in Q1 2025Cash, cash equivalents, and investments of $152.4 million as of March 31, 2025; expected to be sufficient to fund operations into Q4 of 2027 CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the first quarter ended March 3

      5/12/25 4:05:00 PM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Black Diamond Therapeutics to Participate in Upcoming Investor Conferences

      CAMBRIDGE, Mass., March 31, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (NASDAQ:BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced its participation in upcoming investor conferences. Presentation details with President and Chief Executive Officer, Mark Velleca, M.D., Ph.D., are as follows: 24th Annual Needham Virtual Healthcare Conference presentation at 3:00pm ET on Monday, April 7, 2025Stifel 2025 Virtual Targeted Oncology Forum fireside chat at 1:00pm ET on Tuesday, April 8, 2025 Webcasts will be available at the start of the presentations on the investor rel

      3/31/25 8:00:00 AM ET
      $BDTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care